

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)


PCT

(10) International Publication Number
WO 2004/056871 A2

- (51) International Patent Classification⁷: **C07K 14/81** (74) Agent: MEYERS, Hans-Wilhelm; P.O. Box 10 22 41, 50462 Cologne (DE).
- (21) International Application Number: PCT/EP2003/014654
- (22) International Filing Date: 19 December 2003 (19.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 02028465.9 19 December 2002 (19.12.2002) EP
- (71) Applicant (for all designated States except US): **IPF PHARMACEUTICALS** [DE/DE]; Feodor-Lynen-Str. 31, 30625 Hannover (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ADERMANN, Knut** [DE/DE]; Schledenstrasse 5, 30177 Hannover (DE). **KIRCHHOFF, Frank** [DE/DE]; Schmiedgasse 21-3, 89077 Ulm (DE). **MÜNCH, Jan** [DE/DE]; Einsteinstr. 17-2, 89077 Ulm (DE). **SCHULZ, Axel** [DE/DE]; Schneiderberg 28, 30167 Hannover (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: PEPTIDES AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS



(57) Abstract: The invention relates to peptides with biological activity against infection having the amino acid sequence $Z_1\text{-LE-X}_1\text{-IP-X}_2\text{-X}_3\text{-X}_4\text{-P-X}_5\text{-X}_6\text{-X}_7\text{-X}_8\text{-X}_9\text{-X}_{10}\text{-K-X}_{11}\text{-X}_{12}\text{-X}_{13}\text{-X}_{14}\text{-X}_{15}\text{-Z}_2$, wherein X_1 is a lysine, alanine, or aspartic acid; X_2 is a cysteine, methionine or isoleucine; X_3 is a serine, cysteine, lysine or glycine; X_4 is an isoleucine, alanine, phenylalanine or cysteine; X_5 is a proline, D-proline or a substituted L- or D-proline; X_6 is a cysteine or glutamic acid; X_7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X_8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X_9 is an amino acid with an aromatic side chain; X_{10} is a glycine, alanine or asparagine; X_{11} is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X_{12} is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X_{13} is an amino acid with a hydrophobic or an aromatic side chain; X_{14} is an amino acid with a hydrophobic or an aromatic side chain; X_{15} is a phenylalanine or deletion; Z_1 is NH_2 or a sequence of 1 to 10 amino acid residues; Z_2 is COOH or a sequence of 1 to 10 amino acid residues; and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof, and with the proviso that (a) if X_{12} is alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid than X_{13} , X_{14} and X_{15} are phenylalanine, valine and phenylalanine respectively; and/or (b) if X_{12} is phenylalanine, than X_{13} , X_{14} and X_{15} are valine, phenylalanine and a deletion, respectively; and (c) that there are at maximum two cysteine residues in a peptide.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.